

Cite this: *Chem. Sci.*, 2017, 8, 3390

Semiconducting polymer dots with bright narrow-band emission at 800 nm for biological applications†

Dandan Chen,^{‡ac} I-Che Wu,^{‡b} Zhihe Liu,^c Ying Tang,^c Haobin Chen,^c Jiangbo Yu,^b Changfeng Wu^{*a} and Daniel T. Chiu^{*b}

The development of near-infrared (NIR) fluorescent probes is critical for *in vivo* exploration of the fundamental and complex processes in living systems by noninvasive fluorescence imaging techniques. Semiconducting polymer dots (Pdots) are emerging as important probes that exhibit several advantages, such as high brightness and biocompatibility. However, NIR-emitting Pdots are very rare, particularly at the center (~800 nm) of the first optical window of biological tissues (between 650 nm and 950 nm). In this paper, we describe the synthesis of a semiconducting polymer with bright and narrow-band emission at 800 nm. The polymer was designed by incorporating a NIR porphyrin unit into a conjugated backbone; the polymer used a cascade energy transfer to produce the signal. The resulting Pdots possessed a narrow emission bandwidth (FWHM ~ 23 nm) and good fluorescence quantum yield (QY = 8%), which is high for a near-IR emitter. The Pdots were bioconjugated with streptavidin for specific labeling of cellular targets, yielding higher staining index when compared with commercial NIR probes, such as PE-Cy7. Moreover, the NIR polymer was combined with a long-wavelength absorbing polymer to make bright Pdots (QY = 15%) for *in vivo* noninvasive imaging. These NIR Pdots with surface PEGylation led to high-contrast imaging of lymph nodes and tumors in a mouse model. This work highlights the great potential of the NIR Pdots for cellular and *in vivo* imaging applications.

Received 29th January 2017
Accepted 1st March 2017

DOI: 10.1039/c7sc00441a

rsc.li/chemical-science

1. Introduction

Fluorescence imaging techniques are effective tools to non-invasively investigate many fundamental and complex biological processes because they have high signal-to-noise ratios and excellent spatial and temporal resolution.^{1,2} The potential of a fluorescence technique is significantly dependent on the fluorophore's property. Thus the development of novel fluorescent probes is of vital importance for further improvement of many fluorescence-based techniques. For *in vivo* biological applications, near-infrared (NIR) fluorescent probes are highly desirable because of minimal auto-fluorescence interference and high tissue-penetration depth in NIR region due to the weak absorption and scattering of biological species.^{3–5} The most

widely used NIR fluorophores are small-molecule organic dyes (e.g., ICG, Cy7, Atto 740 and Alexa 750).⁶ However, low brightness, small Stokes shift and limited photostability of these NIR dyes are limiting factors for practical biological imaging applications.

Among the strides made in nanotechnology, inorganic semiconductor quantum dots (Qdots) with unique size-tunable emission were introduced to biological studies nearly 20 years ago as fluorescent probes.^{7–9} However, the release of heavy metal ions is a significant concern for living systems. Alternatively, organic dyes can be doped into nanoparticles such as silica and latex beads,^{10–13} which exhibit improved brightness and photostability when compared with molecular dyes alone. In certain cases, nanoparticles with some size range and surface functional groups are promising for applications, such as for sentinel lymph nodes (SLNs) mapping, because they have a long blood-circulation time.^{14–18} However, the usefulness of dye-loaded nanoparticles is severely limited by the low fluorophore concentration and possible dye leaching problems.

Semiconducting polymer dots (Pdots) are emerging as organic fluorescent nanoparticles with high brightness, large Stokes shift, and intriguing energy-transfer properties.^{19–21} These polymeric semiconductors were originally developed for optoelectronic devices,^{22–24} and later used for highly sensitive chemical sensors.^{25,26} In the past decade, the adaptation of

^aDepartment of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong 510855, China. E-mail: wucf@sustc.edu.cn

^bDepartment of Chemistry and Bioengineering, University of Washington, Seattle, Washington 98195, USA. E-mail: chiu@chem.washington.edu

^cState Key Laboratory on Integrated Optoelectronics, College of Electronic Science and Engineering, Jilin University, Changchun, Jilin 130012, China

† Electronic supplementary information (ESI) available: Materials and methods, ¹H NMR and spectra of monomers, DLS, absorption and emission spectra of blended NIR800 Pdots, single particle fluorescence imaging. See DOI: 10.1039/c7sc00441a

‡ These authors contributed equally to this work.



semiconducting polymers as fluorescent probes has received considerable attention in biology and medicine.^{27,28} A large variety of Pdots have been demonstrated for applications such as cellular labeling and tracking,^{29–33} photodynamic and photothermal cancer therapy,^{34–36} drug delivery,^{37,38} *in vivo* optical imaging,^{20,39} photoacoustic imaging,^{40–45} and molecular detection.^{46–48} In contrast with inorganic nanoparticles, one prominent advantage of Pdots is that their optical properties are highly tunable because new polymer structures can be synthesized or small molecular fluorophores can be doped into them.^{49–51} For the latter case, semiconducting polymers as the nanoparticle matrix efficiently absorb light and transfer the energy to the dopant fluorophore, yielding amplified fluorescence when compared with small molecules. Recently, there are major efforts to develop NIR-emitting Pdots for biological applications. Zhang *et al.* synthesized BODIPY-based Pdots and achieved bright narrow-band emission at ~720 nm by cascade energy transfer.⁵² We reported a squaraine-based semiconducting polymer that exhibited efficient NIR narrow-band fluorescence (~704 nm).²¹ Chan *et al.* developed a few Pdot species that extended the emission range to far red and NIR region.⁵³ Pu *et al.* demonstrated multilayered polymer dots for efficient NIR emission.⁵⁴ Despite these progresses, the *in vivo* performance of current Pdots are far from ideal because both the absorption and emission are far away from the center wavelength (~800 nm) of the first optical window of biological tissue (between ~650 nm and 950 nm).

This paper describes the design and synthesis of a NIR semiconducting polymer that emits at 800 nm with high quantum yield, narrow emission bandwidth, and a large Stokes shift. The corresponding Pdots possessed a large absorption cross-section at 488 nm, so they had the potential to work as an excellent fluorescent probe for flow cytometry analysis. Quantitative flow-cytometry results indicated the NIR Pdots exhibit a higher stain index when compared with the commercial NIR probe PE-Cy7 in the specific labeling of cellular targets. Moreover, the NIR800 polymer was combined with a semiconducting polymer with a wide absorption band from 500 to 600 nm, yielding highly fluorescent Pdots for *in vivo* imaging applications. We showed that the PEG-modified Pdots *via* tail-vein injection in a mouse model had long blood-circulation time and led to high-contrast imaging of lymph nodes and tumors. These results indicated that the NIR800 Pdots are promising for a broad range of *in vitro* and *in vivo* bioimaging applications.

2. Results and discussion

2.1. Design and synthesis of NIR800 polymer

For *in vivo* applications, we were inspired to synthesize a semiconducting polymer that emitted at the center wavelength (~800 nm) of the first optical window of biological tissue. The polymer was designed as a cascade energy transfer system that comprises of multiple monomeric units. The chemical structures of the five monomers are shown in Scheme 1. Among those, M1 is made from a porphyrin fluorophore (NIR775) that shows favorable absorption and fluorescence in NIR region. NIR775 is a hydrophobic dye and has been doped into various

conjugated polymers to prepare NIR-emitting Pdots.^{55–59} The close packing of the Pdots allows for energy transfer from the polymer donor to the molecular acceptor, yielding bright fluorescence from the NIR775 dye. However, the emission peak of the NIR775 dye (~775 nm) is still a distance away from the center wavelength of 800 nm. Covering this distance is not trivial for multiplexed detection and *in vivo* imaging that typically use narrow bandpass filters to maximize the signal-to-noise ratio. Furthermore, as the dye is doped into the polymer matrix *via* physical association, there can be several issues, such as dye leaching or segregation, that can decrease the fluorescence of the doped Pdots. In addition, the energy transfer from conventional conjugated polymers to NIR 775 is typically restricted by their small spectral overlap.


Here, we intended to design a narrow-band emissive monomer based on NIR775 and then incorporate this unit into conjugated backbone to produce bright and narrow-band NIR emission. First, the conjugation length of NIR775 unit in the conjugated backbone was enlarged in comparison with the size of the molecular NIR775, which shifted the emission to the long wavelength region (~800 nm). Second, the covalent incorporation overcame the troublesome issues, such as dye leaching and segregation, in the physical doping method. Third, the on-chain energy transfer to the NIR775 unit was more efficient as multiple pathways could occur even when the spectral overlap is negligible.²¹

For the NIR emissive unit, we synthesized the NIR775-Br monomer (M1) by a five-step reaction (Scheme 1a). According to a previous report,⁶⁰ we used 1*H*-benzo[*f*]isoindole-1,3(2*H*)-diimine and 6-bromonaphthalene-2,3-dicarbonitrile as starting materials to form a bromo-substituted porphyrin ring and attached tri-hexylsilane chain to increase the solubility of the M1 unit. Nuclear magnetic resonance (NMR) results confirmed the successful synthesis of the M1 molecule (Fig. S1 and S2†). The M1 monomer exhibited an absorption peak at 772 nm and a fluorescence peak at 777 nm (Fig. S3†). The fluorescence quantum yield of M1 monomer in THF was ~13%, and the full width at half maximum (FWHM) of the emission peak was ~22 nm. These spectroscopic properties of the M1 monomer were similar to those of the NIR775 dye without bromine groups.

Besides the M1 emissive unit, several other monomers (M2–M5) were used in the polymer synthesis to obtain a large absorption coefficient in the visible region and facilitate the occurrence of cascade energy transfer to the M1 unit. The monomer 6-(6-(2,7-dibromo-9-octyl-9*H*-fluorene-9-yl)hexyl)-4,8-di(thiophen-2-yl)-6,7-dihydro-5*H*-[1,2,3]triazolo[4',5':4,5]benzo[1,2-*c*][1,2,5]thiadiazole, called M2, was synthesized according to a reaction previously described (Scheme 1b).^{61,62} The NMR spectrum of M2 was shown in Fig. S4.† The M2 monomer consisted of a chromophore in the side chain of the fluorene unit that had an absorption around 630 nm and an emission around 680 nm (Fig. S5†). In this polymer design, M2 served as an intermediate unit to maximize the cascade energy transfer.

M1 and M2 were copolymerized with three conventional monomer units, which were 9,9-dioctylfluorene-2,7-diboronic acid bis(1,3-propanediol)ester (M3), 4,7-dibromobenzo[*c*][1,2,5]





Scheme 1 (a) Synthetic route of monomers M1. (b) Synthetic route of monomers M2. (c) Synthetic route of NIR800 polymer by Suzuki coupling reaction.

oxadiazole (M4), and 4,7-bis(5-bromothiophen-2-yl)benzo[c][1,2,5]thiadiazole (M5). The polymerization was conducted *via* palladium-catalyzed Suzuki coupling to synthesize the NIR800 polymer (Scheme 1c). The molecular weight of the resulting polymer was determined to be $\sim 27\,652$ daltons with a polydispersity of ~ 2.9 by gel permeation chromatography. As shown in Fig. S6,[†] the absorption of the polymer in THF solution was consistent with the feeding ratio of the five monomers. The NIR800 polymer in THF solution showed a broad fluorescence band in visible region because of its major conjugated backbone structure. In the nanoparticle form, however, the same polymer could yield NIR narrow-band fluorescence because of the efficient intra- and inter-chain exciton diffusion and effective energy funneling to the M1 unit.


2.2. Preparation and characterizations of NIR800 Pdts

The NIR800 polymer was used to prepare Pdts by the reprecipitation method.⁶³ During the preparation, the polymer chains folded and collapsed because of hydrophobic interactions, resulting in stable aqueous solutions of nanometer-sized Pdts (Scheme 2). In contrast to the NIR775-doped Pdts, the NIR800 Pdts were directly and reliably produced from the precursor polymer, reducing the batch-to-batch variation that occurs with the dye doping method. This is particularly important because

the dye doping concentration was typically low (~ 1 wt%) to maintain a high quantum yield.

The NIR800 Pdts exhibited spherical morphology with an average diameter of 16 nm, as determined by dynamic light scattering (DLS) and transmission electron microscopy (TEM) (Fig. 1a). The surface of Pdts was functionalized by blending a small portion (20 wt%) of poly(styrene maleic anhydride) (PSMA), yielding the zeta potential of -36.5 mV and abundant surface carboxyl group for subsequent bioconjugation. As shown by spectroscopic measurements (Fig. 1b), the absorption of the NIR800 Pdts was comparable to that of the precursor polymer, presenting a broad absorption spectrum from 400 nm to 600 nm because of the presence of multiple monomers (M2–M5). Thus, these Pdts were suitable as fluorescent probes for fluorescence imaging and flow cytometry applications. Notably, the Pdts exhibited narrow-band fluorescence with an emission peak at ~ 800 nm and a FWHM of 23 nm, a quantum yield of $\sim 8\%$ and a Stokes shift of ~ 330 nm. The quantum yield of the Pdts was comparable to or higher than the values reported for good NIR fluorophores, such as indocyanine green (ICG, $\sim 2\%$),⁶ NIR7.0 ($\sim 2.5\%$)⁶⁴ and NIR775 ($\sim 7\%$).⁵⁵ Moreover, the emission band width (~ 23 nm) was much narrower than those of NIR dyes and inorganic quantum dots. In addition, the per-particle brightness of the Pdts was more than two orders of magnitude





Scheme 2 Schematic illustration of the preparation of NIR800 Pdots for specific cellular labeling and blended NIR800 Pdots for tumor and lymph-node imaging.

higher than those of the small dye molecules because of the extraordinary absorption cross section.

2.3. Bioconjugation and specific cellular labeling with NIR800 Pdots

Next, we explored the use of the NIR Pdots for specific cell-surface and subcellular labeling. The NIR800 Pdots with surface carboxyl groups was conjugated to streptavidin *via* the EDC-catalyzed coupling method. After conjugation with streptavidin, the size of NIR800 Pdots was increased from 16 nm to 26 nm in diameter and the zeta potential changed from -36 mV to -27 mV (Fig. S7†), indicating successful streptavidin conjugation on the Pdot surface. Then, MCF-7 cells were incubated with biotinylated, monoclonal anti-EpCAM antibodies followed by incubation with Pdot-bioconjugates (Scheme 2). Fig. 1c shows the flow-cytometry results of the MCF-7 cells labeled with Pdots in comparison with the commercial probe PE-Cy7. As seen from the figure, the Pdot-bioconjugates, combined with the primary antibody, were highly specific for the cell labeling in comparison to the control in the absence of the antibody.

We evaluated the labeling performance of the NIR800 Pdots and compared it with that of PE-Cy7, which is a commonly used NIR fluorescent probe for flow cytometry. For each probe, the staining index was calculated by the ratio of the mean fluorescence intensity of positive population to the mean fluorescence intensity of negative population. The staining index of NIR800 Pdots was determined to be ~ 138 , which was significantly higher than the ~ 88 obtained for PE-Cy7. However, the cell labeling brightness by Pdots was slightly lower than that of PE-Cy7. Fluorescent imaging further confirmed that the cells were specifically labeled by NIR800 Pdots, as the strong fluorescent signal was detected from the positively labeled cells (Fig. 1d). In addition, fluorescent imaging showed that the NIR800 Pdot-streptavidin could also specifically label microtubule structures in the presence of biotinylated anti-tubulin antibody (Fig. 1e). No fluorescent signal was observed from the negative-control samples in the absence of the antibody, confirming specific and effective cellular labeling without non-specific binding. Taken together, the above results demonstrate that the NIR Pdots were highly specific for labeling cellular and subcellular structures.






Fig. 1 Characterizations of NIR800 Pdots and specific cell labeling by NIR800 Pdots. (a) Hydrodynamic diameter of the NIR800 Pdots. The inset shows a representative TEM image. The scale bar represents 100 nm. (b) Spectral character of the NIR800 Pdots. (c) Flow cytometry of MCF-7 cells labeled with NIR800 Pdots or PE-Cy7 dye via specific antigen–antibody and streptavidin–biotin interaction with nonspecific labeled cells as control. (d) Fluorescence imaging of cell-surface marker (EPCAM) in MCF-7 cells labeled with Pdot–streptavidin. The scale bar represents 20 μ m. (e) Imaging of microtubules in MCF-7 cells labeled with Pdot–streptavidin. In d and e, the right panels show MCF-7 cells incubated sequentially with primary antibody and Pdot–streptavidin; the left panels show control samples in which the cells were incubated with Pdot–streptavidin alone (no primary antibody). The scale bar represents 20 μ m.

2.4. Preparation and characterization of blended NIR800 polymer dots

We use a polymer blending strategy to enhance the light absorption of the Pdots in the long wavelength region. The absorption of the NIR800 polymer is dominant in blue region, which is not suitable for *in vivo* imaging (Fig. 1b). We synthesized a semiconducting polymer PFDHTBT (chemical structure shown in Scheme 2), which exhibited strong absorption band in green region and broad emission from 600 nm to 800 nm (Fig. 2). By taking advantage of the efficient intra-particle energy transfer inside Pdots,⁶⁵ we intended to shift the light-absorption wavelength and enhance the fluorescence quantum yield of the NIR800 polymer for *in vivo* imaging applications. The PFDHTBT as the donor and the NIR800 polymer as the acceptor showed reasonable spectral overlap (Fig. 2a), indicating that the energy transfer could occur *via* Förster mechanism.

The blended Pdots consisting of the two polymers at variable fractions (0 to 30 wt%) were prepared by using reprecipitation method. As shown by the optical spectroscopy in Fig. S8,[†] the fluorescence of PFDHTBT was increasingly quenched with the increasing fraction of the NIR800 polymer. At the blending fraction of 25 wt%, the Pdots exhibited minimal fluorescence from the PFDHTBT polymer, but strong fluorescence from the NIR800 polymer, indicating the presence of efficient energy transfer from PFDHTBT to NIR800 polymer (Fig. 2b). As a result, the blended Pdots possessed a broad absorption band from 500 nm to 600 nm




Fig. 2 Characterizations of blended NIR800 Pdots. (a) Spectral overlap between the emission of PFDHTBT and the absorption of the NIR800 polymer. (b) Absorption and emission spectra of blended NIR800 Pdots. (c) Ambient-light and fluorescence images of PFDHTBT Pdots and the blended NIR800 Pdots under the same excitation, but different emission, channels using 655 nm and 809 nm band-pass filters, respectively. (d) Hydrodynamic diameter of the blended NIR800 Pdots. The inset shows a representative TEM image. The scale bar represents 100 nm. (e) Fluorescence stability of blended NIR800 Pdots in DMEM medium supplemented with 10% FBS and colloidal stability of blended NIR800 Pdots dispersed in water after continuous incubation at 37 °C. (f) Cell viability of MCF-7 cells incubated with different concentration of blended NIR800 Pdots for 24 hours.

in comparison to the pure NIR800 Pdots. In particular, the blended Pdots exhibited a quantum yield ($\sim 15\%$) for the narrow-band emission, which was apparently enhanced in comparison to the pure NIR800 Pdots ($\sim 8\%$). The enhanced quantum yield was likely attributable to the reduced chain–chain aggregation of the NIR800 polymer in the blended Pdots. Fig. 2c showed the fluorescent images of aqueous solutions of PFDHTBT Pdots and blended NIR800 Pdots collected by a small-animal imaging system. The two samples at the same concentration were excited by the same light source and their emissions were collected by using 655/40 nm and 809/40 nm band-pass filters. The fluorescent signal from the NIR channel was comparable to the red channel. Single-particle imaging and intensity statistics were performed to compare the per-particle brightness of the blended NIR800 Pdots with Qdot800. As shown in Fig. S9,[†] the average brightness of Pdots was about two times higher than that of Qdot800.

Blood-circulation time is a key parameter for *in vivo* targeted delivery of imaging probes and drug molecules. Polyethylene glycol (PEG) groups are typically used for surface functionalization to mask the nanoparticles from the host's immune system and prolong their circulatory time.^{66–68} A functional polymer consisting of long-chain PEG groups (PS-PEG-COOH) was co-condensed with the polymer blends (PFDHTBT and NIR800) to prepare PEGylated NIR Pdots (Scheme 2). The PEGylated NIR800 Pdots exhibited spherical morphology with an average diameter of 18 nm, as determined by DLS and TEM (Fig. 2d). The zeta potential (-33 mV) of the PEG-Pdots was smaller than that of the PSMA-Pdots (-43 mV), most likely because of the presence of the PEG groups on the Pdot surface. The quantum yields of both the PSMA-Pdots and PEG-Pdots were determined to be $\sim 15\%$, indicating that the surface-functional groups did not affect fluorescence brightness of Pdots.



The stability of the NIR Pdots in biological media was evaluated. The Pdots were incubated with DMEM medium supplemented with 10% fetal bovine serum (FBS) at 37 °C. At designated time points, the fluorescence spectra of Pdots in medium and hydrodynamic diameter of Pdots dispersed in water were measured with QE-2100 spectrometer and dynamic light scattering instrument, respectively (Fig. 2e). From the data, we found the Pdots retained more than 95% of its initial fluorescence intensity after two-week storage at 37 °C. The diameter of Pdots is basically unchanged during two-week storage. Therefore, the Pdots is stable in biological environment. The cytotoxicity of NIR Pdots was evaluated on MCF-7 cells by measuring the cell viability with a colorimetric MTT assay. After the MCF-7 cells incubated with different concentrations of NIR 800 Pdots for 24 hours, cytotoxic effects were not observed for high Pdots concentrations, such as 100 $\mu\text{g mL}^{-1}$ (Fig. 2f), indicating the minimal cellular toxicity of the Pdots in this concentration range. Therefore, the red-shifted absorption, high brightness, the narrow-band emission, and biocompatibility of the blended NIR Pdots will be useful for both fluorescence imaging and multiplexed applications.

2.5. Lymph nodes and tumor imaging by blended NIR800 Pdots

First, *in vivo* imaging of the PEGylated NIR800 Pdots was examined in health ICR mice that were administered with PEG-NIR Pdots through the tail vein. The mice receiving PSMA-NIR Pdots injection were also presented for comparative studies. Whole-body fluorescence images of the Pdots-injected mice were subsequently collected at designated time intervals. As shown in Fig. 3a, the PSMA-NIR Pdots were quickly accumulated into liver within a few minutes post-injection. The fluorescence intensity of liver reached maximum in 30 minutes post-injection, and then remained relatively steady for the rest of the time during the first day. Because of the high penetration depth of NIR fluorescence, the liver of mouse was clearly mapped across peritoneum. Fluorescent signals were hardly detected from the body of the mouse because of the combined effect of short blood circulation and quick accumulation of the PSMA-NIR Pdots in liver. In contrast, the PEG-NIR Pdots showed distinct blood-circulation kinetics. Fig. 3b shows whole-body fluorescence images of a mouse that received a PEG-NIR Pdots injection. As clearly seen from the figure, the fluorescence of liver reached maximum at a much longer time scale (~ 24 hours) as compared to the PSMA-NIR Pdots (~ 30 minutes), indicating the apparently prolonged blood circulation of PEG-NIR Pdots. Besides the liver, fluorescence was detected from the body because of the blood circulation as well as the strong fluorescent signal from several spots in the chest and flank. These strong fluorescent spots were attributed to the lymph nodes, as further confirmed by anatomical analysis.

The whole-body fluorescence imaging enabled quantitative analysis of the pharmacokinetics of the Pdots in live mice. We monitored the fluorescence intensity changes in several locations on the mouse body, which corresponded to blood vessel, skin, lymph node, and liver. Fig. 3c and d show the intensity




Fig. 3 Dynamic imaging of live mice receiving tail-vein injection of PSMA-Pdots or PEG-Pdots. (a) Fluorescence imaging of the mouse intravenously injected with PSMA-NIR Pdots at designated time points. (b) Fluorescence imaging of the mouse intravenously injected with PEG-NIR Pdots at designated time points. The number 1, 2, 3, 4 in (a) and (b) represent lymph nodes, liver, blood vessel and skin ground, respectively. (c) Fluorescence intensity analysis of NIR Pdots in skin background and blood vessel of abdomen from PSMA-NIR Pdots injected mouse. (d) Fluorescence intensity analysis of NIR Pdots in liver and lymph nodes from PSMA-NIR Pdots injected mouse. (e) Fluorescence intensity analysis of NIR Pdots in skin background and blood vessel of abdomen from PEG-NIR Pdots injected mouse. (f) Fluorescence intensity analysis of NIR Pdots in liver and lymph nodes from PEG-NIR Pdots injected mouse.

plots for the mice that received the PSMA-NIR Pdots injection while Fig. 3e and f are for the mice that received the PEG-NIR Pdots injections. As indicated by these results, the fluorescent signal from the skin of the mice injected with PSMA-NIR Pdots quickly decreased to the background level in one hour. However, for the mice injected with PEG-NIR Pdots, the fluorescent signal of skin was essentially unchanged for 2 days. Again, this significant difference is because of the long-chain PEG groups on the Pdots that helped to reduce adsorption of blood protein and prevented the Pdots from rapid clearance by the reticuloendothelial system.

Moreover, we observed strong fluorescent signals from the lymph nodes from the mice receiving the PEG-NIR Pdots injection. The signal increased over 24 hours and then began to decrease. After opening the skin of abdomen, the fluorescent signal of lymph nodes and liver were observed clearly (Fig. 4a). The ratio of the fluorescent signals from lymph nodes to that from the skin was about 10.5; the liver-to-skin fluorescence-signal ratio was about 3.8. The high signal-to-noise ratio makes the NIR Pdots a promising probe for *in vivo* fluorescence imaging.

The distribution of the PEG-NIR Pdots in different organs of the mice was investigated. As shown by fluorescence imaging of the organs collected from the mice (Fig. 4b and c), the Pdots were accumulated dominantly in liver, lymph nodes, and slightly in spleen. The strong fluorescence of the PEG-NIR Pdots in the lymph nodes reveals a promising application for SLN mapping as well as for precise surgical dissection of the lymph nodes.






Fig. 4 Biodistributions of PEG-NIR Pdts in ICR mice. (a) Whole-body imaging of mouse 24 hours after tail-vein injection of PEG-NIR Pdts. (b) Ambient-light images and fluorescent images of liver, lung, spleen, kidney and heart from the mouse injected with PEG-NIR Pdts. (c) Ambient-light images and fluorescence of lymph nodes from the mouse injected with PEG-NIR Pdts. (d) Images collected 5 min after injections of PEG-NIR Pdot (right) and methylene blue dye (left) into the right paws of the mouse. (e) Fluorescent images and ambient-light images collected 2 h and 4 h injection into the left paws of the mouse, respectively.

A SLN is the first lymph node to receive lymphatic drainage from the site of a tumor. Therefore, a sentinel lymph node biopsy (SLNB) is very important for the detection of cancer metastasis.^{69–71} The feasibility of NIR Pdts as fluorescent probe for the detection of SLNs was evaluated by a comparative study with a conventional dye staining method. Methylene blue is widely used blue dye for staining SLNs.⁷² The Pdts and methylene blue dye were intradermally injected into the paws of mice to mimic the administration route of SLNs contrast agents. The images were acquired by a small-animal imaging system 5 minutes post-injection. The images of the mouse injected PEG-NIR Pdts is shown in Fig. 4d. The high quantum yield and enhanced retention in lymph nodes of PEG-NIR Pdts allowed the lymph node and lymphatic vessels to be clearly seen. The signal-to-noise ratio of the lymph nodes imaged by the PEG-NIR Pdts was clearly superior to that by methylene blue. In addition, when the lymph node mapping was done 2 h and 4 h post-injection of PEG-NIR Pdts and methylene blue dye, the NIR signal from the Pdts was still clearly seen (Fig. 4e). However, the lymph node stained with methylene blue was hardly visible. As small-molecule dyes, methylene blue can quickly flow through the target area, so the time window for imaging is typically short. In contrast, PEG-NIR Pdts with larger diameters have favorable accumulation and retention in lymph nodes. Therefore, the high imaging sensitivity and long retention time in lymph nodes make the PEG-NIR Pdts a promising contrast agent for fluorescence-guided SLN mapping, allowing for real-time guidance throughout a surgery procedure.

Finally, we demonstrated using the PEGylated NIR Pdts for simultaneous tumor imaging and lymph-node mapping in tumor-bearing mice. The whole-body fluorescence imaging was conducted at designated time points in the mice after tail-vein

injection of the Pdts. As indicated by the imaging (Fig. 5a), the fluorescent signal was first observed in the liver and lymph nodes, which was consistent with the imaging results of the tumor-free mice receiving PEGylated NIR Pdts. However, due to the long blood-circulation time and the enhanced permeability and retention effect of tumor, the Pdts were gradually accumulated in the tumor; the fluorescent signal reached its maximum at 24 h after the Pdts injection. The region of interest in the images showed that the NIR signal of the tumor, relative to that of the surrounding tissue, was 2.1 ± 0.3 (2 h), 3.1 ± 0.3 (8 h), 4.0 ± 0.3 (12 h) and 5.1 ± 0.6 (24 h) (Fig. 5b). The prominent retention of Pdts at tumor site is beneficial for tumor imaging and therapy. The Pdts have the potential to be used both as imaging probes and drug carriers.

After opening of the abdominal skin, strong fluorescent signals were detected and the margin of tumor and lymph nodes were clearly seen (Fig. 5c). This observation indicated the potential of the Pdts for image-guided surgery for tumor and SLN resection. The distribution of PEG-NIR Pdts was evaluated at 24 hours post tail-vein injection. The mice were euthanized and the organs, including heart, liver, spleen, lung, kidney, tumor and lymph nodes, were collected. Fluorescent images of Pdts in the organs were obtained by a small-animal imaging system. The fluorescent images showed that the injected PEG-NIR Pdts were mainly distributed to the liver, lymph nodes and tumor (Fig. 5d inset). The quantitative analysis of the Pdts' distribution was performed by analyzing the fluorescent signals of organs from Pdot-injected mice ($n = 3$). Normally, due to reticuloendothelial system's uptake of Pdts, the fluorescent signal is dominant in liver in comparison to the other organs. However, because of the increased blood-circulation time of the PEG-NIR Pdts in this case, the fluorescent intensity of lymph nodes was significantly higher than that of the liver; the fluorescent signal from the tumor was also enhanced (Fig. 5d). Therefore, the PEG-NIR Pdts, with their suitable size and high




Fig. 5 Simultaneous tumor imaging and lymph-node imaging of MCF-7 tumor-bearing nude mice with PEG-NIR Pdts. (a) Fluorescent images of mouse injected with PEG-NIR Pdts collected at designated time points. (b) Fluorescent signal ratio of tumor to background during 24 hour after Pdts injection. (c) Bright-field and fluorescent images of the same mouse opening of abdomen skin 24 hours post Pdot injection. (d) Quantitative fluorescence analysis of the Pdts in liver, lung, spleen, kidney, heart, tumor and lymph nodes ($n = 3$). Inset shows the overlap image of fluorescence image and bright-field image of liver, lung, spleen, kidney, heart, tumor and lymph nodes.



brightness in NIR region, have the potential to be important contrast agents for tumor and lymph-node imaging.

3. Conclusion

We synthesized a NIR800 semiconducting polymer by introducing multiple monomeric units into one polymer backbone *via* Suzuki coupling. The resulting Pdots exhibited a large absorption cross-section, a narrow emission peak (FMHW = 23 nm), and high quantum yields (QY = 8%). The Pdots were effectively excited with a 488 nm laser, making them suitable for flow cytometry and cellular imaging applications. We performed bioconjugation and specific cellular labeling using the streptavidin–Pdot conjugates. Flow cytometry results indicated that the Pdots showed higher staining index in comparison with the commercial probe PE-Cy7. Furthermore, the NIR800 polymer was blended with a long-wavelength absorbing polymer to produce Pdots (QY = 15%) for *in vivo* applications. The PEGylated Pdots exhibited long blood-circulation time and effectively accumulated to the lymph nodes and tumors, yielding high-contrast fluorescence mapping for precise surgery. These results indicate these NIR Pdots are promising probes for biological assays and contrast agents for clinical imaging applications.

Acknowledgements

C.W. thanks the Key Program of National Natural Science Foundation of China (NSFC 61335001, 61222508) and Thousand Young Talents Program for support of this work, and D.T.C. acknowledges support from the National Institute of Health (CA186798) and the University of Washington. J. Yu and D. T. Chiu have financial interest in Lamprogen, which has licensed the described technology from the University of Washington.

Notes and references

- S. Falkner, S. Grade, L. Dimou, K. K. Conzelmann, T. Bonhoeffer, M. Gotz and M. Hubener, *Nature*, 2016, **539**, 248–253.
- Y. Shiba, T. Gomibuchi, T. Seto, Y. Wada, H. Ichimura, Y. Tanaka, T. Ogasawara, K. Okada, N. Shiba, K. Sakamoto, D. Ido, T. Shiina, M. Ohkura, J. Nakai, N. Uno, Y. Kazuki, M. Oshimura, I. Minami and U. Ikeda, *Nature*, 2016, **538**, 388–391.
- Z. Guo, S. Park, J. Yoon and I. Shin, *Chem. Soc. Rev.*, 2014, **43**, 16–29.
- A. L. Vahrmeijer, M. Hutteman, J. R. van der Vorst, C. J. H. van de Velde and J. V. Frangioni, *Nat. Rev. Clin. Oncol.*, 2013, **10**, 507–518.
- L. Yuan, W. Y. Lin, K. B. Zheng, L. W. He and W. M. Huang, *Chem. Soc. Rev.*, 2013, **42**, 622–661.
- U. Resch-Genger, M. Grabolle, S. Cavaliere-Jaricot, R. Nitschke and T. Nann, *Nat. Methods*, 2008, **5**, 763–775.
- W. C. Chan and S. Nie, *Science*, 1998, **281**, 2016–2018.
- M. Bruchez, M. Moronne, P. Gin, S. Weiss and A. P. Alivisatos, *Science*, 1998, **281**, 2013–2016.
- S. J. Rosenthal, J. C. Chang, O. Kovtun, J. R. McBride and I. D. Tomlinson, *Chem. Biol.*, 2011, **18**, 10–24.
- C. L. O'Connell, R. Nooney and C. McDonagh, *Biosens. Bioelectron.*, 2016, **91**, 190–198.
- S. W. Bae, W. Tan and J. I. Hong, *Chem. Commun.*, 2012, **48**, 2270–2282.
- M. Montalti, L. Prodi, E. Rampazzo and N. Zaccheroni, *Chem. Soc. Rev.*, 2014, **43**, 4243–4268.
- L. Cerdán, E. Enciso, V. Martin, J. Bañuelos, I. López-Arbeloa, A. Costela and I. García-Moreno, *Nat. Photonics*, 2012, **6**, 621–626.
- W. J. Akers, C. Kim, M. Berezin, K. Guo, R. Fuhrhop, G. M. Lanza, G. M. Fischer, E. Daltrozzo, A. Zumbusch, X. Cai, L. V. Wang and S. Achilefu, *ACS Nano*, 2010, **5**, 173–182.
- Y. W. Noh, S. H. Kong, D. Y. Choi, H. S. Park, H. K. Yang, H. J. Lee, H. C. Kim, K. W. Kang, M. H. Sung and Y. T. Lim, *ACS Nano*, 2012, **6**, 7820–7831.
- S. De Koker, J. Cui, N. Vanparijs, L. Albertazzi, J. Grooten, F. Caruso and B. G. De Geest, *Angew. Chem., Int. Ed.*, 2016, **55**, 1334–1339.
- S. Kim, Y. T. Lim, E. G. Soltesz, A. M. De Grand, J. Lee, A. Nakayama, J. A. Parker, T. Mihaljevic, R. G. Laurence, D. M. Dor, L. H. Cohn, M. G. Bawendi and J. V. Frangioni, *Nat. Biotechnol.*, 2004, **22**, 93–97.
- B. Ballou, L. A. Ernst, S. Andreko, T. Harper, J. A. J. Fitzpatrick, A. S. Waggoner and M. P. Bruchez, *Bioconjugate Chem.*, 2007, **18**, 389–396.
- C. Wu, B. Bull, C. Szymanski, K. Christensen and J. McNeill, *ACS Nano*, 2008, **2**, 2415–2423.
- C. Wu, S. J. Hansen, Q. Hou, J. Yu, M. Zeigler, Y. Jin, D. R. Burnham, J. D. McNeill, J. M. Olson and D. T. Chiu, *Angew. Chem., Int. Ed.*, 2011, **50**, 3430–3434.
- I. C. Wu, J. Yu, F. Ye, Y. Rong, M. E. Gallina, B. S. Fujimoto, Y. Zhang, Y. Chan, W. Sun, X. H. Zhou, C. Wu and D. T. Chiu, *J. Am. Chem. Soc.*, 2014, **137**, 173–178.
- Q. Pei, G. Yu, C. Zhang, Y. Yang and A. J. Heeger, *Science*, 1995, **269**, 1086.
- C. D. Muller, A. Falcou, N. Reckefuss, M. Rojahn, V. Wiederhorn, P. Rudati, H. Frohne, O. Nuyken, H. Becker and K. Meerholz, *Nature*, 2003, **421**, 829–833.
- J. Peet, J. Y. Kim, N. E. Coates, W. L. Ma, D. Moses, A. J. Heeger and G. C. Bazan, *Nat. Mater.*, 2007, **6**, 497–500.
- J. S. Yang and T. M. Swager, *J. Am. Chem. Soc.*, 1998, **120**, 11864–11873.
- D. T. McQuade, A. E. Pullen and T. M. Swager, *Chem. Rev.*, 2000, **100**, 2537–2574.
- C. Wu and D. T. Chiu, *Angew. Chem., Int. Ed.*, 2013, **52**, 3086–3109.
- J. Yu, Y. Rong, C. T. Kuo, X. H. Zhou and D. T. Chiu, *Anal. Chem.*, 2016, **89**, 42–56.
- C. Wu, T. Schneider, M. Zeigler, J. Yu, P. G. Schiro, D. R. Burnham, J. D. McNeill and D. T. Chiu, *J. Am. Chem. Soc.*, 2010, **132**, 15410–15417.
- G. Jin, D. Mao, P. Cai, R. Liu, N. Tomczak, J. Liu, X. Chen, D. Kong, D. Ding, B. Liu and K. Li, *Adv. Funct. Mater.*, 2015, **25**, 4263–4273.



- 31 X. Feng, G. Yang, L. Liu, F. Lv, Q. Yang, S. Wang and D. Zhu, *Adv. Mater.*, 2012, **24**, 637–641.
- 32 L. Feng, L. Liu, F. Lv, G. C. Bazan and S. Wang, *Adv. Mater.*, 2014, **26**, 3926–3930.
- 33 D. Ding, D. Mao, K. Li, X. Wang, W. Qin, R. Liu, D. S. Chiam, N. Tomczak, Z. Yang, B. Tang, D. Kong and B. Liu, *ACS Nano*, 2014, **8**, 12620–12631.
- 34 H. Shi, X. Ma, Q. Zhao, B. Liu, Q. Qu, Z. An, Y. Zhao and W. Huang, *Adv. Funct. Mater.*, 2014, **24**, 4823–4830.
- 35 H. Yuan, B. Wang, F. Lv, L. Liu and S. Wang, *Adv. Mater.*, 2014, **26**, 6978–6982.
- 36 J. Geng, C. Sun, J. Liu, L. D. Liao, Y. Yuan, N. Thakor, J. Wang and B. Liu, *Small*, 2015, **11**, 1603–1610.
- 37 Y. Liu, K. Li, J. Pan, B. Liu and S. S. Feng, *Biomaterials*, 2010, **31**, 330–338.
- 38 Y. Liu, K. Li, B. Liu and S. S. Feng, *Biomaterials*, 2010, **31**, 9145–9155.
- 39 D. Ding, K. Li, Z. S. Zhu, K. Y. Pu, Y. Hu, X. Jiang and B. Liu, *Nanoscale*, 2011, **3**, 1997–2002.
- 40 K. Pu, A. J. Shuhendler, J. V. Jokerst, J. Mei, S. S. Gambhir, Z. Bao and J. Rao, *Nat. Nanotechnol.*, 2014, **9**, 233–239.
- 41 K. Pu, J. Mei, J. V. Jokerst, G. Hong, A. L. Antaris, N. Chattopadhyay, A. J. Shuhendler, T. Kurosawa, Y. Zhou, S. S. Gambhir, Z. Bao and J. Rao, *Adv. Mater.*, 2015, **27**, 5184–5190.
- 42 Q. Q. Miao, Y. Lyu, D. Ding and K. Y. Pu, *Adv. Mater.*, 2016, **28**, 3662–3668.
- 43 C. Xie, P. K. Upputuri, X. Zhen, M. Pramanik and K. Pu, *Biomaterials*, 2016, **119**, 1–8.
- 44 J. Zhang, X. Zhen, P. K. Upputuri, M. Pramanik, P. Chen and K. Pu, *Adv. Mater.*, 2016, DOI: 10.1002/adma.201604764.
- 45 Y. Lyu, Y. Fang, Q. Miao, X. Zhen, D. Ding and K. Fu, *ACS Nano*, 2016, **10**, 4472–4481.
- 46 K. Pu, A. J. Shuhendler and J. Rao, *Angew. Chem., Int. Ed.*, 2013, **52**, 10325–10329.
- 47 X. Zhen, C. Zhang, C. Xie, Q. Miao, K. L. Lim and K. Pu, *ACS Nano*, 2016, **10**, 6400–6409.
- 48 Y. Wang, B. Liu, A. Mikhailovsky and G. C. Bazan, *Adv. Mater.*, 2010, **22**, 656–659.
- 49 B. Stender, S. F. Völker, C. Lambert and J. Pflaum, *Adv. Mater.*, 2013, **25**, 2943–2947.
- 50 P. J. Wu, S. Y. Kuo, Y. C. Huang, C. P. Chen and Y. H. Chan, *Anal. Chem.*, 2014, **86**, 4831–4839.
- 51 S. Y. Liou, C. S. Ke, J. H. Chen, Y. W. Luo, S. Y. Kuo, Y. H. Chen, C. C. Fang, C. Y. Wu, C. M. Chiang and Y. H. Chan, *ACS Macro Lett.*, 2016, **5**, 154–157.
- 52 X. Zhang, J. Yu, Y. Rong, F. Ye, D. T. Chiu and K. Uvdal, *Chem. Sci.*, 2013, **4**, 2143–2151.
- 53 H. Y. Liu, P. J. Wu, S. Y. Kuo, C. P. Chen, E. H. Chang, C. Y. Wu and Y. H. Chan, *J. Am. Chem. Soc.*, 2015, **137**, 10420–10429.
- 54 H. Zhu, Y. Fang, X. Zhen, N. Wei, Y. Gao, K. Q. Luo, C. Xu, H. Duan, D. Ding, P. Chen and K. Pu, *Chem. Sci.*, 2016, **7**, 5118–5125.
- 55 Y. Jin, F. Ye, M. Zeigler, C. Wu and D. T. Chiu, *ACS Nano*, 2011, **5**, 1468–1475.
- 56 M. Palmer, K. Pu, S. Shao and J. Rao, *Angew. Chem.*, 2015, **127**, 11639–11642.
- 57 L. Xiong, F. Cao, X. Cao, Y. Guo, Y. Zhang and X. Cai, *Bioconjugate Chem.*, 2015, **26**, 817–821.
- 58 Y. Zhang, F. Ye, W. Sun, J. Yu, I. C. Wu, Y. Rong, Y. Zhang and D. T. Chiu, *Chem. Sci.*, 2015, **6**, 2102–2109.
- 59 S. Li, X. Q. Shen, L. Li, P. Y. Yuan, Z. P. Guan, S. Q. Yao and Q. H. Xu, *Langmuir*, 2014, **30**, 7623–7627.
- 60 M. K. Lowery, A. J. Starshak, J. N. Esposito, P. C. Krueger and M. E. Kenney, *Inorg. Chem.*, 1965, **4**, 128.
- 61 Y. Dong, W. Cai, X. Hu, C. Zhong, F. Huang and Y. Cao, *Polymer*, 2012, **53**, 1465–1472.
- 62 J. Liu, J. Cao, S. Shao, Z. Xie, Y. Cheng, Y. Geng, L. Wang, C. Jing and F. Wang, *J. Mater. Chem.*, 2008, **18**, 1659–1666.
- 63 C. Wu, C. Szymanski, Z. Cain and J. McNeill, *J. Am. Chem. Soc.*, 2007, **129**, 12904–12905.
- 64 C. Bouteiller, G. Clave, A. Bernardin, B. Chipon, M. Massonneau, P. Y. Renard and A. Romieu, *Bioconjugate Chem.*, 2007, **18**, 1303–1317.
- 65 C. Pan, K. Sugiyasu and M. Takeuchi, *Chem. Commun.*, 2014, **50**, 11814–11817.
- 66 Q. Xu, L. M. Ensign, N. J. Boylan, A. Schön, X. Gong, J. C. Yang, N. W. Lamb, S. Cai, T. Yu, E. Freirel and J. Hanes, *ACS Nano*, 2015, **9**, 9217–9227.
- 67 M. A. Miller, Y. R. Zheng, S. Gadde, C. Pfirschke, H. Zope, C. Engblom, R. H. Kohler, Y. Iwamoto, K. S. Yang, B. Askevold, N. Kolishetti, M. Pittet, S. J. Lippard, O. C. Farokhzad and R. Weissleder, *Nat. Commun.*, 2015, **6**, 8692.
- 68 E. Blanco, H. Shen and M. Ferrari, *Nat. Biotechnol.*, 2015, **33**, 941–951.
- 69 L. Q. Xiong, A. J. Shuhendler and J. H. Rao, *Nat. Commun.*, 2012, **3**, 1193.
- 70 M. G. Harisinghani, J. Barentsz, P. F. Hahn, W. M. Deserno, S. Tabatabaei, C. H. van de Kaa and R. Weissleder, *N. Engl. J. Med.*, 2003, **348**, 2491–2499.
- 71 D. L. Morton, J. F. Thompson, A. J. Cochran, N. Mozzillo, R. Elashoff, R. Essner, D. S. Reintgen, O. E. Nieweg, D. F. Roses, H. J. Hoekstra, C. P. Karakousis, D. S. Reintgen, B. J. Coventry, E. C. Glass and H. J. Wang, *N. Engl. J. Med.*, 2006, **355**, 1307–1317.
- 72 T. N. Erpelding, C. Kim, M. Pramanik, L. Jankovic, K. Maslov, Z. Guo, J. A. Margenthaler, M. D. Pashley and L. V. Wang, *Radiology*, 2010, **256**, 102–110.

